Skip to main content

Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

Publication ,  Journal Article
Cameron, ML; Schell, WA; Bruch, S; Bartlett, JA; Waskin, HA; Perfect, JR
Published in: Antimicrob Agents Chemother
November 1993

Yeast strains isolated from the oropharynx of 87 consecutive patients infected with human immunodeficiency virus type 1 were examined for in vitro susceptibility to fluconazole. Candida albicans was isolated from 73 patients. Fifty-one patients had received antifungal therapy in the month preceding the yeast infection. Thirty-two patients had symptomatic oropharyngeal candidiasis. The MICs were correlated with azole use and with clinical symptoms and signs. Although there is overlap between groups, in vitro testing identified a large group of patients for whose yeast isolates the fluconazole MICs were high and who remained symptomatic while receiving azole therapy. This study supports the ability of in vitro testing to predict the clinical outcome of mucosal fungal infections. The study also demonstrates that azole resistance of oropharyngeal yeasts is a common problem in patients infected with human immunodeficiency virus type 1 and that this azole resistance has clinical relevance.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Antimicrob Agents Chemother

DOI

ISSN

0066-4804

Publication Date

November 1993

Volume

37

Issue

11

Start / End Page

2449 / 2453

Location

United States

Related Subject Headings

  • Yeasts
  • Oropharynx
  • Microbiology
  • Microbial Sensitivity Tests
  • Male
  • Humans
  • HIV-1
  • HIV Seropositivity
  • Fluconazole
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cameron, M. L., Schell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A., & Perfect, J. R. (1993). Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother, 37(11), 2449–2453. https://doi.org/10.1128/AAC.37.11.2449
Cameron, M. L., W. A. Schell, S. Bruch, J. A. Bartlett, H. A. Waskin, and J. R. Perfect. “Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.Antimicrob Agents Chemother 37, no. 11 (November 1993): 2449–53. https://doi.org/10.1128/AAC.37.11.2449.
Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–53.
Cameron, M. L., et al. “Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.Antimicrob Agents Chemother, vol. 37, no. 11, Nov. 1993, pp. 2449–53. Pubmed, doi:10.1128/AAC.37.11.2449.
Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453.

Published In

Antimicrob Agents Chemother

DOI

ISSN

0066-4804

Publication Date

November 1993

Volume

37

Issue

11

Start / End Page

2449 / 2453

Location

United States

Related Subject Headings

  • Yeasts
  • Oropharynx
  • Microbiology
  • Microbial Sensitivity Tests
  • Male
  • Humans
  • HIV-1
  • HIV Seropositivity
  • Fluconazole
  • Female